Different Inactivating Mutations of the Mineralocorticoid Receptor in Fourteen Families Affected by Type I Pseudohypoaldosteronism
The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
Abstract
We have analyzed the human mineralocorticoid receptor (hMR) gene in 14 families with autosomal dominant or sporadic pseudohypoaldosteronism (PHA1), a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Six heterozygous mutations were detected. Two frameshift mutations in exon 2 (insT1354, del8bp537) and one nonsense mutation in exon 4 (C2157A, Cys645stop) generate truncated proteins due to premature stop codons. Three missense mutations (G633R, Q776R, L979P) differently affect hMR function. The DNA binding domain mutant R633 exhibits reduced maximal transactivation, although its binding characteristics and ED(50) of transactivation are comparable with wild-type hMR. Ligand binding domain mutants R776 and P979 present reduced or absent aldosterone binding, respectively, which is associated with reduced or absent ligand-dependent transactivation capacity. Finally, P979 possesses a transdominant negative effect on wild-type hMR activity, whereas mutations G633R and Q776R probably result in haploinsufficiency in PHA1 patients. We conclude that hMR mutations are a common feature of autosomal dominant PHA1, being found in 70% of our familial cases. Their absence in some families underscores the importance of an extensive investigation of the hMR gene and the role of precise diagnostic procedures to allow for identification of other genes potentially involved in the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autosomal dominant type 1 pseudohypoaldosteronism (PHAI) is caused by inactivating mutations in the mineralocorticoid receptor (642, 643).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [643]
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Nuclear Hormone Receptors and Gene Expression
Aranda, A., & Pascual, A. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1269 · Cited by 1,570
Krawczak, M., Reiss, J., & Cooper, D. (1992) · Human Genetics · doi:10.1007/bf00210743 · Cited by 1,324
A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes
Liu, H.-X., Cartegni, L., Zhang, M. Q., & Krainer, A. R. (2001) · Nature Genetics · doi:10.1038/83762 · Cited by 477
Geller, D. S., Rodriguez-Soriano, J., Boado, A. V., Schifter, S., Bayer, M., Chang, S. S., & Lifton, R. P. (1998) · Nature Genetics · doi:10.1038/966 · Cited by 417
Multiple aspects of mineralocorticoid selectivity
Farman, N., & Rafestin-Oblin, M.-E. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.2.f181 · Cited by 268
HANUKOGLU, A. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-936 · Cited by 192
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Bledsoe, R. K., Madauss, K. P., Holt, J. A., Apolito, C. J., Lambert, M. H., Pearce, K. H., Stanley, T. B., Stewart, E. L., Trump, R. P., Willson, T. M., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504098200 · Cited by 218
Geller, D. S., Zhang, J., Zennaro, M.-C., Vallo-Boado, A., Rodriguez-Soriano, J., Furu, L., Haws, R., Metzger, D., Botelho, B., Karaviti, L., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005111188 · Cited by 131
“Furthermore, two previously described patients with adPHA1 have MR mutations that are not carried by either parent, although formal genotyping to prove parental identity was not performed (7,8).”
BackgroundSelf-citationClinical and Molecular Features of Type 1 Pseudohypoaldosteronism
Riepe, F. G. (2009) · Hormone Research in Paediatrics · doi:10.1159/000224334 · Cited by 138
“Mutations in the LBD most often disturb aldosterone binding. Several variants associated with adPHA1 have been described. By the use of three-dimensional protein modeling the underlying structural disturbances have been delineated. This was especially useful for the functional characterization of different regions of…”
BackgroundNagase, M., Ayuzawa, N., Kawarazaki, W., Ishizawa, K., Ueda, K., Yoshida, S., & Fujita, T. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.185520 · Cited by 120
Lessons from studying monogenic disease for common disease
Peltonen, L., Perola, M., Naukkarinen, J., & Palotie, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl060 · Cited by 105
“Another set of rare syndromes, resulting from mutations in the mineralocorticoid receptor gene (24) affect the activity of this receptor, an important regulator of ENaC activity (25).”
Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism
Pujo, L., Fagart, J., Gary, F., Papadimitriou, D. T., Claës, A., Jeunemaître, X., & Zennaro, M. (2006) · Human Mutation · doi:10.1002/humu.20371 · Cited by 98
“…600228; SCNN1B, MIM] 600760; SCNN1G, MIM] 600761), we and others have found several inactivating mutations in the NR3C2 gene in renal, autosomal dominant, or sporadic PHA1 [Geller et al., 1998; Nystrom et al., 2004; Riepe et al., 2003, 2004; Sartorato et al., 2003, 2004a,b; Tajima et al., 2000].”
BackgroundSelf-citationLearning Physiology from Inherited Kidney Disorders
van der Wijst, J., Belge, H., Bindels, R. J. M., & Devuyst, O. (2019) · Physiological Reviews · doi:10.1152/physrev.00008.2018 · Cited by 79
Aldosterone resistance: Structural and functional considerations and new perspectives
Zennaro, M., Hubert, E.-L., & Fernandes-Rosa, F. L. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.04.023 · Cited by 81
Self-citationFaresse, N. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.04.015 · Cited by 84
Glucocorticoid and mineralocorticoid receptors and associated diseases
Kino, T., & Chrousos, G. P. (2004) · Essays in Biochemistry · doi:10.1042/bse0400137 · Cited by 67
“[32] reported a large study analysing 14 families with an autosomal-dominant PHA1 phenotype and found six hetrozygotic mutations.”
BackgroundRiepe, F. G., Finkeldei, J., SANCTIS, L. D., Einaudi, S., Testa, A., Karges, B., Peter, M., Viemann, M., Grötzinger, J., Sippell, W. G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1161 · Cited by 69
“(27), the affected father of our patient shows no clinical signs of PHA1.”
BackgroundInfluentialInactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism
Sartorato, P., Khaldi, Y., Lapeyraque, A. L., Armanini, D., Kuhnle, U., Salomon, R., Caprio, M., Viengchareun, S., Lombès, M., & Zennaro, M. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.017 · Cited by 70
Self-citationCrystal Structure of the Mineralocorticoid Receptor DNA Binding Domain in Complex with DNA
Hudson, W. H., Youn, C., & Ortlund, E. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107000 · Cited by 62
“Mutation of this residue to arginine affects receptor activation without affecting its affinity for DNA [39].”
BackgroundStructural and molecular determinants of mineralocorticoid receptor signalling
Großmann, C., Almeida‐Prieto, B., Nolze, A., & de la Rosa, D. Á. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15746 · Cited by 67
“Interestingly, the mutation Gly633Arg in the MR lever arm reduces MR-mediated transactivation and also produces PHA1 (Sartorato et al., 2003).”
BackgroundA molecular update on pseudohypoaldosteronism type II
Pathare, G., Hoenderop, J. G. J., Bindels, R. J. M., & San‐Cristobal, P. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00440.2013 · Cited by 58
“The gold standard for diagnosis is unresponsiveness to administration of exogenous mineralocorticoids (68, 69).”
Background30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor mutations
Zennaro, M., & Fernandes-Rosa, F. L. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0089 · Cited by 62
“Conversely, in some cases, MR mutations identified in PHA1 patients have allowed the identification of crucial amino acids involved in given receptor functions (Sartorato et al. 2003, 2004 a ).”
BackgroundSelf-citationThe Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
GPR48 Increases Mineralocorticoid Receptor Gene Expression
Wang, J., Li, X., Ke, Y., Lu, Y., Wang, F., Fan, N., Sun, H., Zhang, H., Liu, R., Yang, J., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011040351 · Cited by 48
Sartorato, P., Cluzeaud, F., Fagart, J., Viengchareun, S., Lombès, M., & Zennaro, M. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0408 · Cited by 48
“Mutations G633R, Q776R, and L979P were recreated into mammalian expression vectors to elucidate molecular mechanisms underlying the physiopathology of autosomal dominant PHA1.”
BackgroundInfluentialSelf-citationAlexander, R. T., & Bitzan, M. M. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.08.011 · Cited by 49
Thiazide‐Induced Hyponatraemia: Epidemiology and Clues to Pathogenesis
Glover, M., & Clayton, J. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00286.x · Cited by 46
Adrenal cortex and its disorders
Miller, W. L., & Flück, C. E. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00022-6 · Cited by 60
Fernandes-Rosa, F. L., Hubert, E.-L., Fagart, J., Tchitchek, N., Gomes, D. C., Jouanno, E., Benecke, A., Rafestin-Oblin, M. E., Jeunemaı̂tre, X., Antonini, S. R. R., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1486 · Cited by 41
Self-citationTubular Disorders of Electrolyte Regulation
Devuyst, O., Konrad, M., Jeunemaître, X., & Zennaro, M. (2009) · Springer eBooks · doi:10.1007/978-3-540-76341-3_38 · Cited by 36
Self-citationClinical features and molecular basis of pseudohypoaldosteronism type 1
Tajima, T., Morikawa, S., & Nakamura, A. (2017) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.26.109 · Cited by 38
“(26) also reported the functional consequences of the G633R, Q776R, and L979P MR mutations.”
BackgroundMénard, J., & Pascoe, L. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000226183.98439.b3 · Cited by 35
Mineralocorticoid Action in the Aldosterone-Sensitive Distal Nephron
Verrey, F., Hümmler, E., Schild, L., & Rossier, B. C. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50035-8 · Cited by 34
Riepe, F. G., Krone, N. P., Morlot, M., Peter, M., Sippell, W. G., & Partsch, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031555 · Cited by 29
“(14) described two frameshift mutations in exon 2, one nonsense mutation in exon 4, and three missense mutations in exons 3, 5, and 9 in a group of 14 families.”
BackgroundThe Adrenal Cortex and Its Disorders
Miller, W. L., Achermann, J. C., & Flück, C. E. (2008) · Elsevier eBooks · doi:10.1016/b978-141604090-3.50017-x · Cited by 33
Progress and Future Aspects in Genetics of Human Hypertension
Zhao, Q., Kelly, T. N., Li, C., & He, J. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0388-6 · Cited by 33
Nyström, A., Bondeson, M.-L., Skanke, N., Mårtensson, J., Strömberg, B., Gustafsson, J., & Annerén, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030762 · Cited by 28
Balsamo, A., Cicognani, A., Gennari, M., Sippell, W. G., Menabò, S., Baronio, F., & Riepe, F. G. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02330 · Cited by 25
Fernandes-Rosa, F. L., de Castro, M., Latronico, A. C., Sippell, W. G., Riepe, F. G., & Antonini, S. R. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0605 · Cited by 21
Fernandes-Rosa, F. L., Bueno, A. C., de Souza, R. M., de Castro, M., dos Santos, J. E., Foss, M. C., Zennaro, M., Bettiol, H., Barbieri, M. A., & Antonini, S. R. R. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346627 · Cited by 17
Self-citationFeinstein, Y., Yerushalmi, B., Loewenthal, N., Alkrinawi, S., Birk, O. S., Parvari, R., & Hershkovitz, E. (2014) · Hormone Research in Paediatrics · doi:10.1159/000358327 · Cited by 17
Hanukoglu, A., Vargas‐Poussou, R., Landau, Z., Yosovich, K., Hureaux, M., & Zennaro, M. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2020.105755 · Cited by 18
Self-citationTuhan, H., Çatlı, G., Anık, A., Önay, H., Dündar, B. N., Böber, E., & Abacı, A. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0170 · Cited by 16
“J Pediatr Endocr Met 2015; 28(5-6): 701–704”
BackgroundAldosterone Deficiency and Resistance
Arai, K., Papadopoulou‐Marketou, N., & Chrousos, G. P. (2016) · Cited by 15
Kamide, K., Yang, J., Kokubo, Y., Takiuchi, S., Miwa, Y., Horio, T., Tanaka, C., Banno, M., Nagura, J., Okayama, A., et al. (2005) · Hypertension Research · doi:10.1291/hypres.28.703 · Cited by 15
The Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 37
Hatta, Y., Nakamura, A., Hara, S., Kamijo, T., Iwata, J., Hamajima, T., Abe, M., Okada, M., Ushio, M., Tsuyuki, K., et al. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0330 · Cited by 16
“Several studies have shown that the renal form of PHA1 has a broad phenotypic range [7-10].”
BackgroundLema, I., Amazit, L., Lamribet, K., Fagart, J., Blanchard, A., Lombès, M., Cherradi, N., & Viengchareun, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-04838-8 · Cited by 17
Huey, C. L., Riepe, F. G., Sippell, W. G., & Yu, A. S. L. (2004) · American Journal of Nephrology · doi:10.1159/000080672 · Cited by 13
Development and Diseases of the Collecting Duct System
Chen, L., Higgins, P. J., & Zhang, W. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-51436-9_7 · Cited by 16
“In 14 kindreds with sporadic or adPHA1, there are 6 heterozygous NR3C2 mutations, which impact MR structure and function differently (Sartorato et al. 2003).”
BackgroundAutosomal dominant pseudohypoaldosteronism type 1 with a novel splice site mutation in MRgene
Kanda, K., Nozu, K., Yokoyama, N., Morioka, I., Miwa, A., Hashimura, Y., Kaito, H., Iijima, K., & Matsuo, M. (2009) · BMC Nephrology · doi:10.1186/1471-2369-10-37 · Cited by 10
“To test the pathogenic mechanism, Sartorato et al showed in co-transfection experiments that the two mutated receptors they identified, Q776R and L979P, exerted a dominant negative effect on the wild type receptors, and stated that this dominant negative effect is necessary to give rise to autosomal dominant PHA1 [7].”
BackgroundInfluentialUchida, N., Shiohara, M., Miyagawa, S., Yokota, I., & Mori, T. (2009) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2009.22.1.91 · Cited by 8
“MR sequencing include all translated exons (4-11) of the MR gene and the exon-intron boundaries.”
BackgroundRenal Tubular Disorders of Electrolyte Regulation in Children
Devuyst, O., Belge, H., Konrad, M., Jeunemaître, X., & Zennaro, M. (2015) · Springer eBooks · doi:10.1007/978-3-662-43596-0_34 · Cited by 10
Self-citationReceptor Transduction Pathways Mediating Hormone Action
Kublaoui, B. M., & Levine, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00003-8 · Cited by 7
A Novel SCNN1A Variation in a Patient with Autosomal-recessive Pseudohypoaldosteronism Type 1
Huneif, M. A., Alhazmy, Z. H., Shoomi, A. M., Alghofely, M. A., Heena, H., Mushiba, A. M., & Alsaheel, A. Y. (2021) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2021.2020.0175 · Cited by 7
“Patients with PHA1 supposedly present in the neonatal period with hyponatremia, hyperkalemia, and metabolic acidosis, and the condition can be diagnosed by significantly elevated plasma aldosterone levels and renin activity (9-11).”
BackgroundO'Connell, S. M., Johnson, S. R., Lewis, B. D., Staltari, L., Peverall, J., Ly, T. T., Martin, A. C., Jones, T. W., Price, G. J., Murch, A. R., et al. (2011) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2011.230 · Cited by 7
“In addition, hyperkalaemia is generally mild and metabolic acidosis not always detectable (10) , although death has been reported (6) .”
BackgroundInfluentialResistência aos mineralocorticóides: pseudo-hipoaldosteronismo tipo 1
Fernandes-Rosa, F. L., & Antonini, S. R. R. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000300004 · Cited by 11
Aldosterone Regulation of Ion Transport
Pearce, D., Bhalla, V., Funder, J. W., & Stokes, J. B. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10006-5 · Cited by 6
Renal tubular disorders of electrolyte regulation in children
Devuyst, O., Belge, H., Konrad, M., Jeunemaître, X., & Zennaro, M. (2016) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-121793 · Cited by 9
“Although haploinsufficiency is sufficient to cause autosomal dominant PHA1 [474, 475], mutated receptors may also exert dominant-negative effects on the wild-type receptor since MR regulate transcription by binding as receptor dimer to regulatory regions of target genes.”
BackgroundInfluentialSelf-citationReceptor transduction pathways mediating hormone action
Kublaoui, B. M., & Levine, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00012-3 · Cited by 6
Ertek, S., & Çağlar, K. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1570868 · Cited by 4
An infant case of pseudohypoaldosteronism type1A caused by a novel NR3C2 variant
Noda, S., Aoyama, K., Kondo, Y., Okamura, J., Suzuki, A., Yamaguchi, N., Yoshida, A., & Miyake, Y. (2021) · Human Genome Variation · doi:10.1038/s41439-021-00173-7 · Cited by 4
Alexander, R. T., & Böckenhauer, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_39 · Cited by 5
Kostakis, I. D., Cholidou, K. G., & Perrea, D. N. (2012) · HORMONES · doi:10.1007/bf03401536 · Cited by 5
“The renal PHA phenotype is due to either haploinsufficiency (loss of one of the two functional alleles) of MR(36,42,44,46,47) or negative dominant effect of the mutated MR on the activity of the wild-type MR.(42) No homozygous MR mutations have ever been detected in humans,(1,9,24) suggesting that the complete absence…”
Inherited Na transport disorders: the taming of the syndromes
Vehaskari, V. M. (2004) · Current Opinion in Pediatrics · doi:10.1097/00008480-200404000-00012 · Cited by 4
Sodium transporters in kidney role in health and disease.
Sahay, M., Narayen, G., & Anuradha, A. (2007) · PubMed · Cited by 4
Inherited Disorders of Sodium and Potassium Handling
Devuyst, O., Zennaro, M., Vargas‐Poussou, R., & Satlin, L. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-52719-8_108 · Cited by 4
Self-citationA case of idiopathic renal hypouricemia
Han, M. H., Park, S. U., Kim, D., Shim, J. W., Shim, J. Y., Jung, H. L., & Park, M. S. (2007) · Korean Journal of Pediatrics · doi:10.3345/kjp.2007.50.5.489 · Cited by 4
Pseudohypoaldosteronism Type 1
Cheong, H. I. (2013) · Journal of genetic medicine · doi:10.5734/jgm.2013.10.2.81 · Cited by 3
Pseudohypoaldosteronism in a premature neonate with severe polyhydramnios in utero
Ahn, S. Y., Shin, S. M., Kim, K.-A., Lee, Y. K., & Ko, S. Y. (2009) · Korean Journal of Pediatrics · doi:10.3345/kjp.2009.52.3.376 · Cited by 3
Nishizaki, Y., Hiura, M., Sato, H., Ogawa, Y., Saitoh, A., & Nagasaki, K. (2016) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.25.135 · Cited by 3
Boyanton, B. L., Zárate, Y. A., Broadfoot, B. G., Kelly, T. J., & Crawford, B. D. (2024) · Laboratory Medicine · doi:10.1093/labmed/lmae005 · Cited by 5
Molecular pathogenesis of renal pseudohypoaldosteronism type 1
Riepe, F. G. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.3.407 · Cited by 2
Alexander, R. T., & Böckenhauer, D. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_36 · Cited by 6
Stewart, P. M., & Quinkler, M. O. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00109-8 · Cited by 1
Aldosterone Receptors and Their Renal Effects: Molecular Biology and Gene Regulation
Gómez-Sánchez, C. E., Gómez-Sánchez, E. P., & Galigniana, M. D. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-373870-7.00022-3 · Cited by 1
Stewart, P. M., & Quinkler, M. O. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00108-8 · Cited by 1
Fernandes-Rosa, F. L. (2023) · Endocrinology · doi:10.1007/978-3-031-27119-9_12 · Cited by 1
Pseudohypaldosteronism Type 1 and Hypertension Exacerbated in Pregnancy
Geller, D. S. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-449851-8.00018-8 · Cited by 2
Bonny, O. (2007) · CRC Press eBooks · doi:10.3109/9781420020946-3 · Cited by 1
Pseudohypoaldosteronism Type 1
Fernandes-Rosa, F. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65188-7
Disorders of the Adrenal Cortex in the Fetus and Neonate
Khattab, A., Narasimhan, M. L., Macdonald, A., Costin, G., & New, M. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814823-5.00048-9
Mutations of the Human Mineralocorticoid Receptor and Targeted Deletion in Model Organisms
Cole, T. J., Fuller, P. J., & Young, M. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813156-5.00021-2 · Cited by 1
Renal Tubular Disorders of Electrolyte Regulation in Children
Devuyst, O., Belge, H., Konrad, M., Jeunemaître, X., & Zennaro, M. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_34-1 · Cited by 2
Self-citationInherited Disorders of Sodium and Potassium Handling
Devuyst, O., Zennaro, M., Vargas‐Poussou, R., & Satlin, L. M. (2021) · Springer eBooks · doi:10.1007/978-3-642-27843-3_108-1 · Cited by 1
Self-citationFernandes-Rosa, F. L. (2023) · Endocrinology · doi:10.1007/978-3-030-44628-4_12-1
Disorders of the Adrenal Cortex in the Fetus and Neonate
Flück, C. E., du Toit, T., & Miller, W. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23940-3.00035-1
Pseudohypoaldosteronism type 1
Fernandes-Rosa, F. L., & Zennaro, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00354-x
Self-citationStéroïdomique corticosurrénalienne par LC-MS/MS : applications en endocrinologie pédiatrique
Travers, S. A. A. (2020) · theses.fr (ABES) · doi:10.70675/84cf9c3bze93ez41dcza251z559f27f3c6a6
Dhananjaya, M. S., Jakkadi, L., Lalitha, P., Rao, L. P., Nagarajappa, V. H., Hegde, A., Reddy, R., Reddy, H., Nair, S. V. G., & Sarathi, V. (2026) · Clinical Endocrinology · doi:10.1111/cen.70196
Metadata
- Authors
- Sartorato, P., Lapeyraque, A.-L., Armanini, D., Kuhnle, U., Khaldi, Y., Salomon, R., Abadie, V., Di Battista, E., Naselli, A., Racine, A., Bosio, M., Caprio, M., Poulet-Young, V., Chabrolle, J.-P., Niaudet, P., De Gennes, C., Lecornec, M.-H., Poisson, E., Fusco, A. M., Loli, P., Lombès, M., & Zennaro, M.-C.
- Affiliations
- University of Padua (IT)
- Hôpital Robert-Debré (FR)
- Ludwig-Maximilians-Universität München (DE)
- Inserm (FR)
- Division of Nephrology (R.S., P.N.), 75015 Paris, France
- Division of General Pediatrics (V.A.), Department of Pediatrics, Necker-Enfants Malades Hospital, 75015 Paris, France
- Institute G. Gaslini (E.D.B., A.N.), Division of Pediatrics I, 16148 Genova, Italy
- Istituto Giannina Gaslini (IT)
- Centro Diagnostico Italiano (IT)
- University of Rome Tor Vergata (IT)
- Division of Neonatology (V.P-Y., J.P.C.), Le Havre Hospital, 76083 Le Havre, France
- Groupe Hospitalier du Havre (FR)
- Division of Pediatrics (C.D.G.), Orsay General Hospital, 91405 Orsay, France
- Institut National de la Santé et de la Recherche Médicale, Unité 478, Faculté de Médecine Xavier Bichat (P.S., Y.K., M.-H.L., E.P., M.L., M.-C.Z.), 75018 Paris, France
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06-01
- Volume
- 88
- Issue
- 6
- Pages
- 2508-2517
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2136975313
- Cited by
- 85
- References
- 42
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 4 · 2015: 3 · 2014: 6 · 2013: 3 · 2012: 4
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- mineralocorticoid receptor, mineralocorticoid resistance, receptor mutations, frameshift mutation, nonsense mutation, missense mutations, DNA-binding domain, ligand-binding domain, transcriptional activation, haploinsufficiency, autosomal dominant inheritance, renal salt wasting, failure to thrive
- MeSH terms
- Female, Humans, Infant, Infant, Newborn, Male, Mutation, Pedigree, Pseudohypoaldosteronism, Transcription, Genetic, Cohort Studies, Receptors, Mineralocorticoid, Mutation, Missense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.